\
&
Contact us
\
&
Contact us
Published on | 2 months ago
Programmes EICThe European Innovation Council (EIC) selected 71 cutting edge companies for funding, combining grants and equity, following the last 2024 EIC Accelerator cut-off in October. They have been selected among 1211 submitted proposals, out of which 431 have been invited to the jury interviews.
21% of the selected companies are led by women (as CEO, CSO or CTO), while there is a geographical spread spanning 16 countries.
Four of the selected companies have benefitted from the ‘Plug In’ scheme. The scheme allows funding bodies managing certified national/regional programmes to submit projects from their portfolio directly to the full application stage of the EIC Accelerator.
A further 330 applications that were assessed positively by the EIC jury, but for which there was insufficient funding available, will be awarded a Seal of Excellence. This recognition helps these companies to find alternative funding sources, including from the Recovery and Resilience Funds and European Regional Development Funds.
3 Belgian organisations will receive blended financing.
More details available here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space AI Continent Deployment: Best use of technologies
The Openverse project hosted last week a high-impact workshop, “National Initiatives and the European Partnership on Virtual Worlds,” aligning stakeholders around the European Commission’s Virtual Worlds strategy. The initiative, rooted in the July 2023 Communication on Web 4.0 and Virtual Worlds, aims to build sustainable, inclus... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
